M. Cecchini

发表

Electronic Intervention to Improve Structured Cancer Stage Data Capture.

Michael Cecchini, K. Adelson, M. Cecchini, 2016, Journal of oncology practice.

The implementation of electronic hematology consults at a VA hospital.

E. Wong, M. Rose, M. Cecchini, 2016, Blood.

Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study

V. Koshkin, N. Housri, M. Karuturi, 2022, JMIR cancer.

A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer

J. Lacy, J. Kortmansky, H. Hochster, 2020, Cancer.

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

A. Grothey, A. Ohtsu, H. Hochster, 2016, BMC Cancer.

2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer

Jie He, R. Rosati, P. Chiu, 2021, Annals of Esophagus.

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

M. Sznol, M. Cecchini, S. Seropian, 2015, Journal of Immunotherapy for Cancer.

Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System.

J. Lacy, K. Johung, M. Cecchini, 2021, Journal of gastrointestinal oncology.

Diagnostic tool to identify and treat DNA repair deficient gastroesophageal adenocarcinomas

Z. Szallasi, I. Csabai, Harshabad Singh, 2022, bioRxiv.

Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer

Tae You Kim, J. Desai, Chen Li, 2022, Communications Medicine.

Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade.

K. Johung, M. Cecchini, Wei Wei, 2021, The oncologist.

Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database.

J. Lacy, A. Sheth, J. Uhlig, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?

Jay K Pahade, M. Cecchini, S. Mahalingam, 2021, Abdominal Radiology.

Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer

C. Hallemeier, S. Jabbour, C. Anker, 2022, American journal of clinical oncology.

A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).

J. Lacy, J. Kortmansky, H. Hochster, 2019, Journal of Clinical Oncology.

Superficial Granulomatous Pyoderma Gangrenosum Involving the Face: A Case Series of Five Patients and a Review of the Literature

S. Walsh, A. Alavi, M. Cecchini, 2021, Journal of cutaneous medicine and surgery.

Atypical Presentation of Congenital Yellow Nail Syndrome in a 2-Year-Old Female

M. Cecchini, N. Kanigsberg, Joseph Doumit, 2013, Journal of cutaneous medicine and surgery.

Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential

Joanna A Gibson, E. Stoffel, J. Sweasy, 2021, British Journal of Cancer.

Targeted Therapies in Advanced Gastric Cancer

M. Cecchini, Timil H Patel, 2020, Current Treatment Options in Oncology.

Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis

R. Salem, J. Lacy, C. Hallemeier, 2020, Clinical and translational radiation oncology.

EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.

J. Sklar, J. Lacy, M. Cecchini, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Challenges with Novel Clinical Trial Designs: Master Protocols

Michael Cecchini, Hildy Dillon, P. LoRusso, 2019, Clinical Cancer Research.

A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer

R. Salem, J. Lacy, J. Kortmansky, 2020, Pancreas.

Impact of early detection on cancer curability: A modified Delphi panel study

B. Monk, M. Broder, H. Beltran, 2022, PloS one.

ARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC).

J. Bendell, N. Giafis, C. Quah, 2021 .

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

A. Chen, K. Schalper, J. Eder, 2023, Cancer research communications.

Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US

C. Gross, T. Hyslop, A. Justice, 2023, JAMA network open.

The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).

A. Barzi, J. Lennerz, R. Kelley, 2020 .

Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop

Paolo P. Provenzano, P. Ascierto, E. Puré, 2023, Journal for ImmunoTherapy of Cancer.

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

A. Grothey, A. Ohtsu, H. Hochster, 2016, BMC Cancer.

Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Y. Kong, J. Lacy, K. Schalper, 2023, Cancer research communications.

Immune Modulation in Interventional Oncology

M. Cecchini, J. Ludwig, Hyun S Kim, 2020 .

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

J. Lacy, J. Kortmansky, S. Boerner, 2023, British journal of cancer.

Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.

J. Lacy, M. Muzumdar, J. Kortmansky, 2024, JAMA oncology.

PD-010Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer

A. Grothey, H. Hochster, K. Pashtoon, 2016 .